Jade Biosciences announced progress in its autoimmune disease drug pipeline, including starting a Phase 3 trial for JADE101 in IgA nephropathy in Q4 2026 and ongoing Phase 1 and 2 trials for other candidates. The company reported a net loss of $35.1 million for Q3 2026, driven by increased R&D and administrative expenses. With $476 million in cash and investments, Jade expects to fund operations through late 2028. These developments position the company for multiple clinical milestones in 2027, aiming to deliver new therapies for autoimmune conditions.
Jade Biosciences reported a net loss of $35.1 million for Q3 2026, with ongoing clinical trials and a strong cash position of $476 million as of late 2026. For readers following the health sector, here is Pluang's market snapshot as of Nov 13, 2026 18:41 WIB: out of 150 priced US health stocks, 93 rose and 49 fell. Notable movers include BNGO at USD 1.01 with a 1-day change of -2.88%, RPRX at USD 67.09 down 2.73%, and AHCO at USD 7.68 down 2.41% with 100% sell order activity on Pluang.
Boralex Inc. announced the issuance of C$600 million in green bonds, split into two series with maturities in 2031 and 2036, bearing interest rates of 4.503% and 5.173% respectively. This marks Boralex's first green-labelled corporate securities offe...
Boralex Inc. announced a private placement of $600 million Canadian dollars in green bonds, split into two series maturing in 2031 and 2036 with interest rates of 4.503% and 5.173%, respectively. This marks Boralex's first issuance of green corporate...
Investec Bank Plc, acting as an exempt principal trader and advisor to DBAY Advisors Limited, disclosed the sale of 25,000 ordinary shares of Logistics Development Group Plc on November 12, 2026. The shares were sold at a price of 23 per unit. There ...
Investec Bank Plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed public dealings in the company's ordinary shares on November 12, 2026. The bank purchased 345,456 shares at prices between 282.561 and 283 pence ...
Ondas Holdings increased its 2026 revenue target to at least $550 million and projects $1.1 billion in sales for 2027, driven by strong growth and planned production expansion. The company reported Q3 revenue of $167.49 million, surpassing estimates ...
